Nancy Lin
, Associate Chief of the · Mass General Brigham
Credentials: · · ·
History
- Present
the · Mass General Brigham
- 1995–1999
1991–1995
Research
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Review · The Lancet Oncology · 2017 · 2,010 citations
RECIST 1.1-Update and clarification: From the RECIST committee
European Journal of Cancer · 2016 · 1,635 citations
Journal of Clinical Oncology · 2012 · 1,150 citations
147 papers
106 papers
- IK
58 papers
47 papers
36 papers
34 papers
28 papers
27 papers · 11 as a resident
Grants
- 2013–2030
Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
National Cancer Institute · P50
PI · $12.3M · Dana-Farber Cancer Inst
- 2011–2014
Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN Loss
National Cancer Institute · R21
PI · $552.8K · University of Tx Md Anderson Can Ctr
Clinical trials
- 2024–2033
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
- 2024–2029
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Principal investigator · Recruiting · Phase 2
Nancy Lin, MD
- 2023–2036
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
- 2018–2026
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Principal investigator · Completed · Phase 2
Nancy Lin, MD